JONATHAN DAVID POWELL, M.D.
Osteopathic Medicine at Wolfe St, Baltimore, MD
License number
Maryland D51364
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-8964
Personal information
See more information about JONATHAN DAVID POWELL at radaris.comName
Address
Phone
3600 41St Ave, Brentwood, MD 20722
3609 Greenway, Baltimore, MD 21218
9 Loran Ct, Elkton, MD 21921
980 Bramleigh Ln, Annapolis, MD 21401
943 N Chester St, Baltimore, MD 21205
Professional information
See more information about JONATHAN DAVID POWELL at trustoria.com
Web / Graphic Designer At Bithgroup Technologies
Web / Graphic Designer At Bithgroup Technologies
Position:
Web / Graphic Designer at BITHGROUP Technologies, President, Project Manager, Graphic Designer at Jonathan Powell Design
Location:
Baltimore, Maryland Area
Industry:
Graphic Design
Work:
BITHGROUP Technologies
- Baltimore, Maryland Area since Jul 2013
-
Web / Graphic Designer
Jonathan Powell Design
since Apr 2008
-
President, Project Manager, Graphic Designer
ThinkJPP, LLC
- Baltimore, Maryland Area Aug 2011 - Jul 2013
-
President, Lead Designer, Project Manager
Digi-Graphics LLC
Jan 2006 - May 2008
-
Lead Web & Graphic Design
Education:
Colorado State University 2008 - 2011
Bachelors of Science, Business Administration: Marketing Front Range Community College 2006 - 2008
Associates of Arts, Digital Media: Graphic Design
Bachelors of Science, Business Administration: Marketing Front Range Community College 2006 - 2008
Associates of Arts, Digital Media: Graphic Design
Skills:
Marketing, Flash, Project Management, Game Design, Graphic Design, Social Media, SEO, Web Design, Adobe Creative Suite, Photoshop, Social Media Marketing, Advertising, Photography, Creative Direction, Branding & Identity, Logo Design, Dreamweaver
Interests:
Innovative design, the gaming industry, music, literature, film, flash, german
Honor & Awards:
Phi Theta Kappa Honor Society, Colorado State College of Business Deans List
Languages:
German
Jonathan David Powell, Baltimore MD
Jonathan David Powell, Baltimore MD
Specialties:
Hematology, Medical Oncology, Hematology
Work:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N Broadway St, Baltimore, MD 21287 JHU Oncology
600 N Wolfe St, Baltimore, MD 21287
401 N Broadway St, Baltimore, MD 21287 JHU Oncology
600 N Wolfe St, Baltimore, MD 21287
Education:
Emory University(1992)
Physician Researcher At The Johns Hopkins Hospital
Physician Researcher At The Johns Hopkins Hospital
Position:
Physician Researcher at The Johns Hopkins Hospital
Location:
Baltimore, Maryland Area
Industry:
Hospital & Health Care
Work:
The Johns Hopkins Hospital
since 2001
-
Physician Researcher
Education:
Dartmouth College
Dr. Jonathan D Powell, Baltimore MD - MD (Doctor of Medicine)
Dr. Jonathan D Powell, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
1650 Orleans St SUITE 443, Baltimore 21287
(410) 502-7887 (Phone), (410) 614-9705 (Fax)
THE BUNTING BLAUSTEIN CANCER
1650 Orleans St, Baltimore 21287
(410) 614-6894 (Phone)
401 N Broadway St SUITE 800, Baltimore 21287
(410) 502-7887 (Phone), (410) 614-9705 (Fax)
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
(410) 955-8964 (Phone), (410) 955-0115 (Fax)
(410) 502-7887 (Phone), (410) 614-9705 (Fax)
THE BUNTING BLAUSTEIN CANCER
1650 Orleans St, Baltimore 21287
(410) 614-6894 (Phone)
401 N Broadway St SUITE 800, Baltimore 21287
(410) 502-7887 (Phone), (410) 614-9705 (Fax)
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
(410) 955-8964 (Phone), (410) 955-0115 (Fax)
Certifications:
Hematology, 2009, Internal Medicine, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1650 Orleans St SUITE 443, Baltimore 21287
401 N Broadway St SUITE 800, Baltimore 21287
THE BUNTING BLAUSTEIN CANCER
1650 Orleans St, Baltimore 21287
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
401 N Broadway St SUITE 800, Baltimore 21287
THE BUNTING BLAUSTEIN CANCER
1650 Orleans St, Baltimore 21287
JOHNS HOPKINS HOSPITAL
401 N Broadway St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Emory University
Graduated: 1992
Johns Hopkins University School Med
Emory University
Graduated: 1992
Johns Hopkins University School Med
Manipulation Of Regulatory T Cell And Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists And Antagonists
Manipulation Of Regulatory T Cell And Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists And Antagonists
US Patent:
2010004, Feb 18, 2010
Filed:
Sep 11, 2006
Appl. No.:
11/991693
Inventors:
Hong Yu - Baltimore MD, US
Drew Pardoll - Brookeville MD, US
Xiaoya Pan - Baltimore MD, US
Charles George Drake - Baltimore MD, US
Jonathan D. Powell - Baltimore MD, US
Ching-Tai Huang - Taipei, TW
Drew Pardoll - Brookeville MD, US
Xiaoya Pan - Baltimore MD, US
Charles George Drake - Baltimore MD, US
Jonathan D. Powell - Baltimore MD, US
Ching-Tai Huang - Taipei, TW
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395, A61K 35/12, A61K 38/16, C07K 16/00, A61P 31/00, C07H 21/00, A61P 35/00, C12N 15/63, A61P 37/06, A01K 67/027, C12Q 1/02
US Classification:
4241721, 424 9371, 424 9321, 514 12, 5303891, 5303873, 536 231, 536 245, 4353201, 536 2353, 800 18, 435 29
Abstract:
We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.
Anti-Cancer Vaccine Composition Comprising An Anti-Cd223 Antibody And Kit Comprising An Anti-Cancer Vaccine And An Anti-Cd223 Antibody
Anti-Cancer Vaccine Composition Comprising An Anti-Cd223 Antibody And Kit Comprising An Anti-Cancer Vaccine And An Anti-Cd223 Antibody
US Patent:
8551481, Oct 8, 2013
Filed:
Oct 22, 2009
Appl. No.:
12/578887
Inventors:
Drew M Pardoll - Brookeville MD, US
Ching-Tai Huang - Taipei, TW
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US
Dario A Vignali - Germantown TN, US
Creg J Workman - Memphis TN, US
Ching-Tai Huang - Taipei, TW
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US
Dario A Vignali - Germantown TN, US
Creg J Workman - Memphis TN, US
Assignee:
The Johns Hopkins University - Baltimore MD
St. Jude Children's Research Hospital, Inc. - Memphis TN
St. Jude Children's Research Hospital, Inc. - Memphis TN
International Classification:
A61K 39/00, A61K 39/395, A61K 39/38, C12P 21/08
US Classification:
4241391, 4241411, 4241841, 5303881, 53038875
Abstract:
Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.
Adenosine Receptor Agonists And Antagonists To Modulate T Cell Responses
Adenosine Receptor Agonists And Antagonists To Modulate T Cell Responses
US Patent:
2011002, Feb 3, 2011
Filed:
Sep 8, 2008
Appl. No.:
12/676741
Inventors:
Jonathan D Powell - Baltimore MD, US
Charles George Drake - Baltimore MD, US
Paul Zarek - McLean VA, US
Charles George Drake - Baltimore MD, US
Paul Zarek - McLean VA, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/395, A61K 39/00, A61P 37/04, A61P 37/06, A61P 35/00, A61P 31/00
US Classification:
4241741, 4241841, 4241301
Abstract:
Described are uses of A2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing T-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents. The application provides methods of treatment and prevention based on the long term effects of the compounds on T cell responses.
Compositions And Methods For Modulating An Immune Response
Compositions And Methods For Modulating An Immune Response
US Patent:
2011022, Sep 22, 2011
Filed:
May 8, 2009
Appl. No.:
12/991654
Inventors:
Charles George Drake - Baltimore MD, US
Drew M. Pardoll - Brookeville MD, US
Jonathan Davie Powell - Baltimore MD, US
Derese Getnet - Baltimore MD, US
Edward Luther Hipkiss - Mechanicsburg PA, US
Joseph Frank Grosso - Pennington NJ, US
Drew M. Pardoll - Brookeville MD, US
Jonathan Davie Powell - Baltimore MD, US
Derese Getnet - Baltimore MD, US
Edward Luther Hipkiss - Mechanicsburg PA, US
Joseph Frank Grosso - Pennington NJ, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/00, C12N 5/02, C07H 21/04, C12N 15/63, C12Q 1/68, A61P 37/00
US Classification:
4241841, 435375, 536 245, 4353201, 435 613
Abstract:
The invention generally features compositions and methods for modulating an immune response. In particular embodiments, such compositions and methods modulate regulatory T cell suppressive activity.
T Cell Regulation
T Cell Regulation
US Patent:
2006024, Oct 26, 2006
Filed:
Mar 1, 2004
Appl. No.:
10/547371
Inventors:
Drew Pardoll - Brookeville MD, US
Ching-Tai Huang - Taipei, TW
Dario Vignali - Bartlett TN, US
Creg Workman - Memphis TN, US
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US
Ching-Tai Huang - Taipei, TW
Dario Vignali - Bartlett TN, US
Creg Workman - Memphis TN, US
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
St Jude Children's Research Hospital Inc. - Memphis TN
St Jude Children's Research Hospital Inc. - Memphis TN
International Classification:
A61K 39/395
US Classification:
424155100
Abstract:
Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.
T Cell Regulation
T Cell Regulation
US Patent:
2013009, Apr 18, 2013
Filed:
Nov 16, 2012
Appl. No.:
13/679485
Inventors:
The Johns Hopkins University - Baltimore MD, US
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US
Dario A. Vignali - Germantown TN, US
Creg J. Workman - Memphis TN, US
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US
Dario A. Vignali - Germantown TN, US
Creg J. Workman - Memphis TN, US
Assignee:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL INC. - Memphis TN
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/395
US Classification:
4241521, 4241721
Abstract:
Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.